- HG-10-102-01
-
- $53.00 / 5mg
-
2025-04-29
- CAS:1351758-81-0
- Min. Order:
- Purity: 99.73%
- Supply Ability: 10g
|
| [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Basic information |
Product Name: | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone | Synonyms: | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone;HG-10-102-01;(4-((5-chloro-4-
(methylamino)pyrimidin-2-yl)amino)-
3-
methoxyphenyl)(morpholino)methano
ne;Methanone, [4-[[5-chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl-;CS-949;LRRK2 INHIBITOR 1;Parkinson’s disease,Leucine-rich repeat kinase 2,inhibit,Ser910,BBB,HG 10 102 01,Radiosynthesis,Mouse embryonic fibroblast cells,Mouse Swiss 3T3 cells,MAP kinase interacting kinase,Ser935,MNK,Mitogen activated protein kinase interacting kinase,HG1010201,PET,Inhibitor,MAPK interacting kinase,HEK293 cells,LRRK2,Positron emission tomography;HG-10-102-01, 10 mM in DMSO | CAS: | 1351758-81-0 | MF: | C17H20ClN5O3 | MW: | 377.83 | EINECS: | | Product Categories: | API;Pharmaceuticals;Intermediates & Fine Chemicals;Heterocycles;Aromatics;Amines;Amines, Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals | Mol File: | 1351758-81-0.mol | ![[4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Structure](CAS/GIF/1351758-81-0.gif) |
| [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Chemical Properties |
Boiling point | 641.1±65.0 °C(Predicted) | density | 1.381±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | insoluble in H2O; ≥18.9 mg/mL in DMSO; ≥7.64 mg/mL in EtOH with ultrasonic | form | solid | pka | 4.60±0.10(Predicted) | color | White to off-white |
| [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Usage And Synthesis |
Description | HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2; IC50 = 20.3 nM). It also inhibits the G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively). HG-10-102-01 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant LRRK2 in cells. When given intraperitoneally, HG-10-102-01 penetrates the blood-brain barrier and inhibits phosphorylation of LRRK2 in the brain as well as the kidney and spleen. | Uses | [4-[[5-Chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinylmethanone is an aminopyrimidine derivative as LRRK2 modulators used for the treatment of Parkinson''s disease. | Definition | ChEBI: HG-10-102-01 is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-{[5-chloro-4-(methylamino)pyrimidin-2-yl]amino}-3-methoxybenzoic acid with the amino group of morpholine. It is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is an aminopyrimidine, a member of morpholines, a monocarboxylic acid amide, an organochlorine compound, a secondary amino compound and an aromatic ether. | in vivo | HG-10-102-01 (0-100 mg/kg, IP, once) shows inhibition of LRRK2 Ser910/Ser935 phosphorylation in kidney, spleen, and brain of mice[1].
HG-10-102-01 (1 mg/kg, IV; 10 mg/kg, PO; once) shows good oral bioavailability (%F = 67), a short half-life of 0.13 h, and low plasma exposure[1]. Animal Model: | Wild type male C57BL/6 mice[1] | Dosage: | 0, 3, 10, 30, 50, and 100 mg/kg | Administration: | IP, once | Result: | Showed near complete dephosphorylation of Ser910 and Ser935 of LRRK2 in all tissues including brain at 100 mg/kg and 50 mg/kg, but only partial inhibition in brain at the 30 and 10 mg/kg doses. |
Animal Model: | Wild type male C57BL/6 mice[1] | Dosage: | 1 mg/kg (IV); 10 mg/kg (PO) | Administration: | IV, PO; once (Pharmacokinetic Analysis) | Result: | Pharmacokinetic Parameters of HG-10-102-01 in male C57BL/6 mice[1].
| IV (1 mg/kg) | PO (10 mg/kg) | Tmax (h) | | 0.25 | Cmax (ng/mL) | 1330 | 1241 | AUClast (ng/mL?h) | 74.85 | 502.34 | AUCINF (ng/mL?h) | 75.06 | 503.41 | T1/2 (h) | 0.13 | | CL (mL/min/kg) | 222.04 | | Vss (L/kg) | 1.68 | | F (%) | | 67 |
|
| references | [1] choi hg1, zhang j, deng x, hatcher jm, patricelli mp, zhao z, alessi dr, gray ns. brain penetrant lrrk2 inhibitor. acs med chem lett. 2012 aug 9;3(8):658-662. epub 2012 jun 18. |
| [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Preparation Products And Raw materials |
|